News headlines about Portola Pharmaceuticals (NASDAQ:PTLA) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Portola Pharmaceuticals earned a news impact score of 0.11 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.7433202186631 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern’s rankings:
A number of brokerages have issued reports on PTLA. Oppenheimer set a $80.00 price objective on shares of Portola Pharmaceuticals and gave the company a “buy” rating in a report on Monday, January 15th. BidaskClub raised shares of Portola Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, December 21st. Goldman Sachs Group started coverage on shares of Portola Pharmaceuticals in a report on Friday, December 1st. They issued a “buy” rating and a $75.00 target price for the company. ValuEngine raised shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. Finally, Citigroup reissued a “buy” rating and issued a $74.00 target price on shares of Portola Pharmaceuticals in a report on Thursday, December 28th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $70.65.
Portola Pharmaceuticals (NASDAQ:PTLA) traded down $0.25 during mid-day trading on Tuesday, hitting $46.04. The company had a trading volume of 479,472 shares, compared to its average volume of 909,757. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.31 and a quick ratio of 8.31. The company has a market capitalization of $3,254.75, a P/E ratio of -10.73 and a beta of 1.18. Portola Pharmaceuticals has a 12-month low of $26.90 and a 12-month high of $67.10.
Portola Pharmaceuticals (NASDAQ:PTLA) last posted its earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.08. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The company had revenue of $3.83 million for the quarter, compared to analyst estimates of $4.71 million. During the same quarter in the previous year, the firm earned ($1.64) earnings per share. The firm’s quarterly revenue was down 58.9% compared to the same quarter last year. analysts predict that Portola Pharmaceuticals will post -4.94 EPS for the current year.
In other news, Director Henry Ward Wolff sold 12,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $47.00, for a total transaction of $564,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 5.50% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/06/portola-pharmaceuticals-ptla-earns-news-sentiment-rating-of-0-11.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.